0001213900-23-045117.txt : 20230601
0001213900-23-045117.hdr.sgml : 20230601
20230601171925
ACCESSION NUMBER: 0001213900-23-045117
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20230601
DATE AS OF CHANGE: 20230601
EFFECTIVENESS DATE: 20230601
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Origin Life Sciences, Inc.
CENTRAL INDEX KEY: 0001573901
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 273705184
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-483151
FILM NUMBER: 23985690
BUSINESS ADDRESS:
STREET 1: 2 RESEARCH WAY
STREET 2: THIRD FLOOR
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: 609-250-6000
MAIL ADDRESS:
STREET 1: 2 RESEARCH WAY
STREET 2: THIRD FLOOR
CITY: PRINCETON
STATE: NJ
ZIP: 08540
FORMER COMPANY:
FORMER CONFORMED NAME: Origin, Inc.
DATE OF NAME CHANGE: 20170501
FORMER COMPANY:
FORMER CONFORMED NAME: Advanced Plasma Therapies, Inc.
DATE OF NAME CHANGE: 20130408
D
1
primary_doc.xml
X0708
D
LIVE
0001573901
Origin Life Sciences, Inc.
2 RESEARCH WAY
THIRD FLOOR
PRINCETON
NJ
NEW JERSEY
08540
(609) 250-6000
DELAWARE
Plasma Jet Technologies, Inc.
Origin, Inc.
Advanced Plasma Therapies, Inc.
Corporation
true
Michael
David
Preston
c/o Origin Life Sciences, Inc.
2 Research Way, Third Floor
Princeton
NJ
NEW JERSEY
08540
Executive Officer
Director
Chief Executive Officer
David
Dantzker
c/o Origin Life Sciences, Inc.
2 Research Way, Third Floor
Princeton
NJ
NEW JERSEY
08540
Executive Officer
Director
Chief Medical Officer
John
Fernandes
c/o Origin Life Sciences, Inc.
2 Research Way, Third Floor
Princeton
NJ
NEW JERSEY
08540
Executive Officer
Chief Financial Officer
Anthony
Brampton
c/o Origin Life Sciences, Inc.
2 Research Way, Third Floor
Princeton
NJ
NEW JERSEY
08540
Director
Victor
Micati
c/o Origin Life Sciences, Inc.
2 Research Way, Third Floor
Princeton
NJ
NEW JERSEY
08540
Director
Jerome
Boda
Korten
c/o Origin Life Sciences, Inc.
2 Research Way, Third Floor
Princeton
NJ
NEW JERSEY
08540
Director
Biotechnology
Decline to Disclose
- 06b
false
2023-05-30
false
true
false
25000
None
None
None
None
NONE
NONE
NONE
XX
Unknown
00000
NY
NEW YORK
false
850000
500000
350000
Corporation and its stockholders are entering into a private placement offering of: (i) up to 425,000 shares of the Corporation's common stock, par value $0.01 per share, at a price per share of $2.00, for gross proceeds of up to $850,000.
false
1
0
0
0
While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.
false
Origin Life Sciences, Inc.
/s/ Michael D. Preston
Michael D. Preston
Chief Executive Officer and Chairman
2023-06-01